Hepsiburada Announces Extraordinary General Assembly Meeting

Hepsiburada will convene an Extraordinary General Assembly on Aug. 14, 2026 to approve a TRY 9,321,419,250 share capital increase. The nominal share capital would rise from TRY 72,368,116.80 (361,840,584 shares) to TRY 86,653,816.80 (433,269,084 shares), with TRY 14,285,700 to nominal value and TRY 9,307,133,550 to share premium. The company plans to disapply Bank of New York Mellon’s pre-emptive rights for the increase, which may be viewed as dilution/capital-structure uncertainty even though no unit price is stated.

Analysis

This reads as a financing-overhang event first and a growth story second. A capital raise of this size can reduce solvency/funding risk, but the market usually prices the dilution before it prices the optionality of a cleaner balance sheet; for a name like HEPS, that means near-term multiple compression is more likely than immediate rerating.

The second-order effect is competitive, not just financial. If management is forced to allocate attention and cash to recapitalization, larger regional e-commerce players with stronger balance sheets can pull forward share gains via promotions, logistics subsidies, and merchant acquisition. BK is not a meaningful direct winner here; any depositary/corporate-action fee uplift is too small to matter to earnings.

Catalyst path is clear: Aug. 14 approval is the headline, but the real risk/reward comes from the disclosed subscription price, anchor participation, and whether pre-emptive rights are effectively waived for existing holders. If the raise is priced at a meaningful discount or used to patch working capital, the stock can stay weak for 1-3 months; if the company frames proceeds as balance-sheet repair with a credible runway extension, the pain can fade over 6-18 months. Falsifier: a strategic investor underwriting at a premium with explicit operating cash burn improvement would weaken the short thesis quickly.

Key Decisions for Investors

• Short HEPS tactically into the Aug. 14 shareholder vote, with a 1-3 month horizon; target the announcement/pricing window. Risk/reward is favorable if the market anticipates 15-25% dilution plus governance overhang. Cover aggressively if the issue is anchored at a premium or if the company signals materially lower cash burn.
• If options are liquid, buy HEPS put spreads expiring 1-2 months after the meeting to express financing-dilution risk without borrow dependency. Use strikes centered around the pre-announcement trading range; thesis fails if terms show a non-dilutive strategic placement.
• Set a hard watch item on the subscription terms: if the raise is larger than the implied ~20% share-count increase or comes with waived pre-emptive participation for insiders/existing holders, add to shorts on confirmation. If the company retains pre-emptive economics for minorities, reduce exposure.
• Do not express this via BK; there is no material P&L linkage. Treat BK as a no-trade in this setup unless a separate, meaningful depositary-services catalyst emerges.